Usha Sundralingam

Dr. Usha Sundralingam

School of Pharmacy, Monash University, Malaysia
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in Foods
Verified
Journal Article
Open access
PDF file
MMMohanambal Moorthy
Mohanambal Moorthy
Usha SundralingamUsha Sundralingam
Usha Sundralingam
Uma PalanisamyUma Palanisamy
Uma Palanisamy
Obesity is a disease growing at an alarming rate and numerous preclinical studies have proven the role of polyphenols in managing this disease. This systematic review explores the prebiotic effect of polyphenols in the management of obesity among animals fed on a high-fat diet. A literature search was carried out in PubMed, Scopus, CINAHL, Web of Science, and Embase databases following the PRISMA guidelines. Forty-four studies reported a significant reduction in obesity-related parameters. Most notably, 83% of the studies showed a decrease in either body weight/visceral adiposity/plasma triacylglyceride. Furthermore, 42 studies reported a significant improvement in gut microbiota (GM), significantly affecting the genera Akkermansia, Bacteroides, Blautia, Roseburia, Bifidobacteria, Lactobacillus, Alistipes, and Desulfovibrio. Polyphenols’ anti-obesity, anti-hyperglycaemic, and anti-inflammatory properties were associated with their ability to modulate GM. This review supports the notion of polyphenols as effective prebiotics in ameliorating HFD-induced metabolic derangements in animal models.

25 August 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Wai-Kit TowWai-Kit Tow
Wai-Kit Tow
PCPui Ying PUI Chee
Pui Ying PUI Chee
Usha SundralingamUsha Sundralingam
Usha Sundralingam
Uma PalanisamyUma Palanisamy
Uma Palanisamy
The therapeutic effects of food rich in ellagitannins have been established to stem from its microbial metabolite, urolithin. Over the past decade, there has been a growing trend in urolithin research pertaining to its pharmacological properties. The purpose of this systematic review is to collate and synthesise all available data on urolithin’s therapeutic ability, to highlight its potential as a pharmaceutical agent, and prospective direction on future research. Methods: This systematic review was written based on the PRISMA guideline and was conducted across Ovid via Embase, Ovid MEDLINE, Cochrane Central Register for Controlled Trials, and Web of Science Core Collection. Results: A total of 41 animal studies were included in this systematic review based on the appropriate keyword. The included studies highlighted the neuroprotective, anti-metabolic disorder activity, nephroprotective, myocardial protective, anti-inflammatory, and musculoskeletal protection of urolithin A, B, and its synthetic analogue methylated urolithin A. The Sirt1, AMPK, and PI3K/AKT/mTOR signalling pathways were reported to be involved in the initiation of autophagy and mitochondrial biogenesis by urolithin A. Conclusions: This review methodically discusses the therapeutic prospects of urolithins and provides scientific justification for the potential development of urolithin A as a potent natural mitophagy inducer for anti-ageing purposes.

25 August 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Usha SundralingamUsha Sundralingam
Usha Sundralingam
SCSrikumar Chakravarthi
Srikumar Chakravarthi
ARAmmu Kutty Radhakrishnan
Ammu Kutty Radhakrishnan
SMSaravanan Muniyandy
Saravanan Muniyandy
Uma PalanisamyUma Palanisamy
Uma Palanisamy
Oral tamoxifen used in the prevention and treatment of ductal carcinoma in situ (DCIS) (estrogen-positive) patients has limited acceptance, due to its adverse side effects. The efficacy of tamoxifen is related to its major metabolite, 4-hydroxytamoxifen. Local transdermal therapy of 4-hydroxytamoxifen to the breast might avert the toxicity of oral tamoxifen, while maintaining efficacy. We aim to study the skin irritancy, as well as to evaluate the efficacy of the developed transfersome formulations, with/without emu oil, using a syngeneic mouse model of breast cancer. We also quantified tamoxifen/4-hydroxytamoxifen concentrations in blood plasma and performed histopathology. The skin irritancy test showed that the pure emu oil and transfersome formulations with or without the emu oil did not cause skin irritancy in the animals studied. A sensitive and specific LC–MS/MS method for the quantification of tamoxifen and 4-hydroxytamoxifen was developed and validated. Studies on tumor volume and necrosis (histopathology) using the breast cancer mouse model showed that the 4-OHT transfersomal formulations, with and without emu oil, showed comparable efficacy with that of orally administered tamoxifen. However, the transfersomal formulations, with and without emu oil, resulted in significantly lower (10.24 ± 0.07 and 32.45 ± 0.48 ng/mL, respectively) plasma concentrations of 4-hydroxytamoxifen, compared to the oral tamoxifen (TAMX) group (634.42 ± 7.54 ng/mL). This study demonstrated the potential use of emu oil in a local transdermal formulation for the treatment of breast cancer and its reduced adverse effects.

24 September 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Wai-Kit TowWai-Kit Tow
Wai-Kit Tow
Asly GohAsly Goh
Asly Goh
Usha SundralingamUsha Sundralingam
Usha Sundralingam
Uma PalanisamyUma Palanisamy
Uma Palanisamy
YSYasodha Sivasothy
Yasodha Sivasothy
The oil palm tree (Elaeis guineensis Jacq.) originates from West and Central Africa, and it is cultivated in Malaysia for its oil-producing fruits. Malaysia is the world’s second largest palm oil producer and the world’s largest exporter to date. Consequently, the Malaysian oil palm industry constantly generates a huge amount of biomass with the major contributor being the leaves. A large percentage of these leaves remain underutilized, making them a promising source of raw materials that can be converted into value-added products. The present review summarizes and discusses the flavonoid composition, total phenolic and flavonoid content, and the in vitro and in vivo pharmacological properties exhibited by the extracts of the leaves of E. guineensis. The purpose of this systematic review is to highlight the potential of valorizing the leaf extracts of the oil palm tree as pharmaceutical and cosmeceutical agents.

30 August 2020 in Journal of Liposome Research
Verified
Journal Article
Closed access
Usha SundralingamUsha Sundralingam
Usha Sundralingam
SMSaravanan Muniyandy
Saravanan Muniyandy
ARAmmu Kutty Radhakrishnan
Ammu Kutty Radhakrishnan
Uma PalanisamyUma Palanisamy
Uma Palanisamy
The anti-inflammatory property of ratite oils as well as its ability to act as a penetration enhancer makes it an ideal agent to be used in transdermal formulations. The present study aims to develop an effective transfersomal delivery of 4-hydroxytamoxifen, an anti-cancer drug, using ratite oil as a carrier agent for the treatment of breast cancer. The 4-hydroxytamoxifen transfersomes were prepared with and without ratite oils using soy phosphatidylcholine and three different edge activators in five different molar ratios using the rotary evaporation-ultrasonication method. Optimal transfersome formulations were selected using physical-chemical characterization and ex vivo studies. Results from physical-chemical characterisation of the developed formulations found sodium taurocholate to be the most suitable edge activator, whichrecorded highest entrapment efficiency of 95.1 ± 2.70% with 85:15, (w/w) and lowest vesicle size of 82.3 ± 0.02 nmwith 75:25, (w/w) molar ratios. TEM and DSC studies showed that the vesicles were readily identified and present in a nearly perfect spherical shape. In addition, formulations with emu oil had better stability than formulations with ostrich oil. Physical stability studies at 4 °C showed that ratite oil transfersomes were stable up to 4 weeks, while transfersomes without ratite oils were stable for 8 weeks. Ex vivo permeability studies using porcine skin concluded that 4-hydroxytamoxifen transfersomal formulations with (85:15, w/w) without emu oil have the potential to be used in transdermal delivery approach to enhance permeation of 4-hydroxytamoxifen, which may be beneficial in the treatment of breast cancer.

12 June 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
SESumita Elendran
Sumita Elendran
VKV. Shiva Kumar
V. Shiva Kumar
Usha SundralingamUsha Sundralingam
Usha Sundralingam
WTWai-Kit Tow
Wai-Kit Tow
UPUma Devi Palanisamy
Uma Devi Palanisamy
Geraniin (GE), an ellagitannin (ET) renowned for its promising health advantages, faces challenges in its practical applications due to its limited bioavailability. This innovative and novel formulation of GE and soyphosphatidylcholine (GE -PL) complex has the potential to increase oral bioavailability, exhibiting high entrapment efficiency of 100.2 +/- 0.8 %, and complexation efficiency of 94.6 +/- 1.1 %. The small particle size (1.04 +/- 0.11 mu m), low polydispersity index (0.26 +/- 0.02), and adequate zeta potential (-26.1 +/- 0.12 mV), indicate its uniformity and stability. Moreover, the formulation also demonstrates improved lipophilicity, reduced aqueous and buffer solubilities, and better partition coefficient. It has been validated by various analytical techniques, including Fourier -transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and X-ray diffraction (XRD) studies. Oral bioavailability and pharmacokinetics of free GE and GE -PL complex investigated in rabbits demonstrated enhanced plasma concentration of ellagic acid (EA) compared to free GE. Significantly, GE, whether in its free form or as part of the GE -PL complex, was not found in the circulatory system. However, EA levels were observed at 0.5 h after administration, displaying two distinct peaks at 2 +/- 0.03 h (T1 max ) and 24 +/- 0.06 h (T2 max ). These peaks corresponded to peak plasma concentrations (C1 max and C2 max ) of 588.82 ng/mL and 711.13 ng/mL respectively, signifying substantial 11 -fold and 5 -fold enhancements when compared to free GE. Additionally, it showed an increased area under the curve (AUC), the elimination half-life (t 1/2 , el) and the elimination rate constant (K e l ). The formulation of the GE -PL complex prolonged the presence of EA in the bloodstream and improved its absorption, ultimately leading to a higher oral bioavailability. In summary, the study highlights the significance of the GE -PL complex in overcoming the bioavailability limitations of GE, paving the way for enhanced therapeutic outcomes and potential applications in drug delivery and healthcare.